Compression Physics of a Hygroscopic High-Molecular-Weight Polysaccharide in Oral Solids

Dry blending of sterile sodium hyaluronate with microcrystalline cellulose PH102 and dibasic calcium phosphate dihydrate before roller compaction is used to manage the free-flowing but electrostatic nature of the powder. Bulk powder exposed to a relative humidity above 60% is pre-dried in a vacuum tray dryer at 25–30 °C under not less than −0.08 MPa for a minimum of 6 h, because surface gel film formation on the particle reduces die filling and increases tablet weight variation. Loss on drying is held below 5.0% by USP <731> before charging. A representative unit formula for a joint-care oral dosage form contains 20 mg to 150 mg sodium hyaluronate per tablet or two-piece HPMC capsule, with microcrystalline cellulose and dibasic calcium phosphate dihydrate as fillers at a total excipient-to-API ratio of 6:1 to 12:1, croscarmellose sodium at 2.0–4.0% w/w as disintegrant, and magnesium stearate at 0.5–1.0% w/w. Magnesium stearate above 1.5% w/w is avoided because the lubricant film over sodium hyaluronate particles delays tablet disintegration in aqueous media and produces a characteristic non-wetting surface. Roller compaction is preferred over direct compression because the powder blend tends to segregate; a roller compactor with 100 mm rolls, 15–25 kN/cm specific compaction force, and a 1.0 mm integral screen produces granules with a tapped density of 0.55–0.75 g/mL and a Hausner ratio below 1.30 measured by USP <616>. Tablet press parameters are set with a precompression force of 5–10 kN and a main compression force of 15–25 kN, producing a hardness of 80–120 N and a disintegration time not exceeding 30 min in 900 mL water at 37 °C using a disintegration apparatus per USP <2040>. Since there is no pharmacopoeial dissolution monograph for oral sodium hyaluronate supplements, release testing relies on weight variation per USP <2091>, disintegration, water content, and sodium hyaluronate assay by hyaluronan-binding protein assay or size-exclusion chromatography. Operational boundaries include storage of finished tablets in aluminium-aluminium blister packs rather than PVC/PVDC because water-vapour transmission above 0.5 g/m²/day can raise hardness and prolong disintegration after three months in accelerated stability chambers at 40 °C/75% RH.

A top-spray fluid-bed granulator with a 28 L product bowl and a 3.0 mm two-fluid nozzle is used for oral dispersible granules when the target dosage form is a single-dose sachet rather than a compressed tablet. Sodium hyaluronate is blended with mannitol and sucrose or isomalt at a ratio of 1:20 to 1:40 to prevent the surface filming observed with hygroscopic diluent systems, then sprayed with a 2.0–4.0% w/w aqueous solution of povidone K30 or hydroxypropyl cellulose L. The binder solution is applied at a spray rate of 8–15 g/min, an inlet air temperature of 50–65 °C, and a product temperature of 30–38 °C; the dew point of the inlet air is controlled below 10 °C to keep the granule moisture below 3.0% by USP <731>. After drying in the same fluid-bed chamber until the outlet-air temperature reaches 45 °C, the granulate is passed through a 710 µm sieve and a 250 µm sieve; the retained middle fraction with a D50 of 150–300 µm is filled into aluminium-lined sachets at 1.0–2.0 g fill weight per unit dose, delivering 20–100 mg sodium hyaluronate. A critical process limitation is the pH of the reconstituted dispersion: an acidic carrier such as citric acid in an effervescent base pushes the pH below 3.0, causing acid-catalyzed depolymerization of the polysaccharide backbone and reducing intrinsic viscosity within 24 h at 25 °C. Finished granules are therefore formulated to give a pH of 5.0–7.0 when dispersed in 100 mL water at 25 °C, and the packaging moisture barrier is specified with a water-vapour transmission rate below 0.1 g/m²/day to preserve the flow and rehydration characteristics. On production-scale lines, batch-to-batch variance in granule flow is most commonly traced to the polyol ratio; replacing more than 20% of the mannitol with sorbitol increases hygroscopicity and produces soft, sticky granules that adhere to the distributor plate of the fluid-bed dryer.

When Terminal Sterilization of Sodium Hyaluronate Solution Is Not Feasible

For parenteral grades with a molecular weight above 1.5 MDa, moist-heat terminal sterilization in an autoclave at 121 °C for 15 min is generally incompatible with the target intrinsic viscosity because the polysaccharide backbone undergoes hydrolytic scission, reducing the weight-average molecular weight by a sufficient margin to shift the product out of specification for intra-articular or ophthalmic use. Aseptic processing is therefore the standard route when the bulk API is received as sterile powder and dissolved in water for injection at a sodium hyaluronate concentration of 8–20 mg/mL for intra-articular solutions or 10–14 mg/mL for ophthalmic viscoelastics. The dissolution vessel is a 316L stainless-steel jacketed tank with a bottom-mounted magnetic stirrer and a nitrogen overlay at 0.2–0.5 bar; dissolution is carried out at 20–35 °C for 6–18 h until the solution is visually homogeneous and free of gel particles. If sterilizing-grade filtration is attempted, a 0.45 µm polyethersulfone prefilter and a 0.22 µm final filter are used, but high-molecular-weight sodium hyaluronate solutions above 1.0% w/v can exhibit dramatic throughput loss because the loose random-coil structure exerts high back-pressure on the membrane; filter capacity is commonly below 0.3 L/m² for a 20,000–80,000 mPa·s solution at 25 °C. Low-molecular-weight grades (0.3–1.0 MDa) may be filtered at 35–50 °C to reduce viscosity, but the thermal history must be validated by size-exclusion chromatography because the same heating step can reduce the molecular weight if retention time exceeds 4 h. Published data for this specific configuration is limited for combined molecular-weight and concentration grades above 15 mg/mL, so filter capacity is qualified empirically on each production lot. Sterility is confirmed by membrane filtration or direct inoculation per USP <71> and Ph. Eur. 2.6.1, bacterial endotoxin is controlled to not more than 0.05 IU/mg by limulus amebocyte lysate testing per USP <85> and Ph. Eur. 2.6.14, and particulate matter in the finished injection is measured by light obscuration per USP <788> with acceptance criteria of not more than 6,000 particles ≥10 µm and 600 particles ≥25 µm per container. The final container is a siliconized Type I borosilicate glass syringe closed with a chlorobutyl plunger stopper; on filling lines, the residual oxygen headspace is kept below 5% v/v to limit oxidative degradation during shelf life.

Intra-articular applications impose a narrow viscosity specification window because the injected material must remain within the joint space during ambulation but still pass through a 25G or 27G thin-wall needle without excessive extrusion force. Pre-filled syringes containing 2.0 mL or 2.5 mL of sodium hyaluronate solution at 8–20 mg/mL are filled under aseptic conditions and terminally inspected for needle-free syringes. The weight-average molecular weight is typically 1.5–3.0 MDa, and the zero-shear dynamic viscosity at 25 °C measured with a cone-and-plate rheometer at 1 s⁻¹ is held between 10,000 mPa·s and 100,000 mPa·s depending on the product's molecular-weight grade; a lower value cannot maintain the hydrodynamic lubrication effect, and a higher value creates unacceptably high extrusion force through the needle. Extrusion force for a 25G needle is controlled to a maximum of 30 N at a crosshead speed of 50 mm/min on a universal testing machine, because physicians report persistent hand fatigue when the force exceeds this threshold in multi-injection treatment protocols. The pH of the finished solution is adjusted with small volumes of 0.1 M sodium hydroxide or hydrochloric acid to a range of 5.5–7.5, and osmolality is adjusted with sodium chloride to 300–400 mOsm/kg measured by freezing-point depression per Ph. Eur. 2.2.35. Bioburden control before sterile filtration or aseptic filling relies on a validated hold time of not more than 24 h at 2–8 °C for the formulated bulk, and the filling line must be qualified with media fills to a contamination rate of not more than 0.1% per EMA Annex 1. The sterile API and finished injection are tested for molecular weight distribution by size-exclusion chromatography with multi-angle light scattering, because the standard viscometric method alone does not distinguish a uniform chain population from a blend of high- and low-molecular-weight fractions. Terminal product labels specify single-use only and the absence of preservatives; multi-dose formulations are not typical for this indication.

What Limits Heat Load in Ophthalmic Surgical Devices Containing Hyaluronic Acid?

In ophthalmic viscoelastic production, the sodium hyaluronate solution is compounded at 10–14 mg/mL in a phosphate-buffered saline matrix with a final pH of 7.0–7.4 and osmolality of 300–350 mOsm/kg, because the corneal endothelium is highly sensitive to hypoosmotic and hyperosmotic stress. The product is used during cataract extraction and intraocular lens implantation as a space-maintaining and tissue-protecting viscoelastic, so the polymer concentration must be sufficient to produce a dynamic viscosity in the range of 40,000–120,000 mPa·s at 1 s⁻¹ for cohesive OVDs, while dispersive formulations use lower molecular weight or lower concentration to achieve a thinner rheological profile. Heat load is the principal restriction in terminal processing: dry-heat sterilization above 160 °C and moist-heat cycles above 121 °C both induce measurable depolymerization, and the resulting reduction in chain length lowers the retention of the anterior chamber depth during surgery. The filled syringes are therefore aseptically processed, and the polymer solution is either sterile-filtered if the molecular weight permits, or compounded from sterile sodium hyaluronate powder. The final device must meet ISO 16672 for ophthalmic viscoelastic devices, including optical clarity, sodium hyaluronate content assay by enzymatic degradation with hyaluronidase, and syringe function tests for extrusion and cannula attachment. Cytotoxicity is evaluated per ISO 10993-5, irritation per ISO 10993-10, and systemic toxicity per ISO 10993-11 with appropriate extraction vehicles. A particular incompatibility is the use of cationic preservatives such as benzalkonium chloride at concentrations above 0.005% w/v; the anionic carboxyl groups of hyaluronic acid form electrostatic complexes with cationic compounds, producing visible precipitates and inconsistent rheological behavior in the final container. Terminal products are filled into Type I glass syringes with a 27G or 30G cannula and sterilized elastomer closures; label storage is 2–25 °C with protection from freezing, because freeze-thaw cycles can cause microgel formation and syringe plunger movement failure on the surgical tray.

Dermal augmentation formulations based on cross-linked sterile sodium hyaluronate require a manufacturing route that intentionally diverges from the non-cross-linked injectable solution process because the terminal implant must resist hyaluronidase-mediated degradation for 6–18 months depending on the anatomical site and product density. Sodium hyaluronate is dissolved in an alkaline phosphate buffer and reacted with 1,4-butanediol diglycidyl ether at a controlled molar ratio relative to the disaccharide repeat unit; the reaction is conducted at 25–40 °C for 12–36 h under nitrogen, followed by neutralization with hydrochloric acid and extensive dialysis or precipitation to remove residual cross-linker. The cross-linked gel is then sieved through calibrated stainless-steel meshes to produce a defined particle size distribution, typically 100–1,000 µm for biphasic fillers; monophasic fillers are homogenized without particle classification. Dynamic oscillatory rheometry is used as the primary release method, with a storage modulus G′ of 200–1,000 Pa and a loss modulus G″ such that tan δ remains below 0.30 at 1 Hz and 25 °C on a rheometer fitted with a 40 mm parallel-plate geometry and a 1.0 mm gap; these values correlate with the lift capacity and tissue integration behavior of the implant. Extrusion force through a 27G or 30G needle is maintained below 30 N at 50 mm/min, and the same lot is tested for residual BDDE by gas chromatography–mass spectrometry with a limit that is validated according to ISO 10993-17 and regional medical-device requirements. Sterility of the final implant is achieved through aseptic processing rather than terminal sterilization, because the cross-linked gel loses its cohesive strength after moist-heat treatment; the sterility test follows USP <71>, endotoxin is controlled per USP <85>, and the packaging system consists of a Type I glass syringe with a silicone-coated plunger and a 27G or 30G thin-wall needle. A specific operational boundary is the high sensitivity of the gel to freeze-thaw cycling: storage below 2 °C can create ice-crystal-induced void defects that are visible as opacity in the gel and cause inconsistent extrusion through the cannula. Incompatibility with cationic drug additives and alcohol-based skin preparatives at the injection site is also documented because the anionic polymer network can dehydrate and temporarily stiffen in contact with high-concentration ethanol.